Every material Form 8-K SAB Biotherapeutics, Inc. has filed with the SEC since May 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SAB Biotherapeutics announced that the FDA granted Fast Track designation to SAB-142, an immunotherapy being developed for new-onset Stage 3 type 1 diabetes. The designation is intended to facilitate development and expedite review for serious conditions with unmet medical need, and the filing says SAB-142 is in a registrational Phase 2b study with topline data anticipated in 2H 2027.
FDA granted Fast Track designation to SAB-142 for new-onset Stage 3 type 1 diabetes, announced October 13, 2026
SAB-142 is being evaluated in the registrational Phase 2b SAFEGUARD study, with enrollment expected to be completed in Q4 2026
Topline data from the SAFEGUARD study are anticipated in 2H 2027
The filing does not disclose financial figures related to the designation
SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., University of Florida, to support the PRISE-hATG clinical study of SAB-142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis. SAB BIO will co-fund the study, which extends its clinical evaluation of SAB-142 beyond the Phase 2b SAFEGUARD trial; the filing gives no financial amount for the grant or the company's share of costs.
Breakthrough T1D awarded the grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida, dated July 7, 2026.
PRISE-hATG evaluates SAB-142 in patients 100 days to 2 years from a Stage 3 T1D diagnosis.
SAB BIO will co-fund the study alongside the complementary Phase 2b SAFEGUARD trial.
The filing does not disclose grant or co-funding amounts.
SAB Biotherapeutics entered a Master Manufacturing Services Agreement with Emergent BioSolutions Canada, effective April 28, 2026, under which Emergent will make SAB-142 clinical and commercial supply at its Canadian facility. The agreement sets a minimum aggregate spend of $36 million following any FDA approval of the product, and gives Emergent exclusive manufacturing rights during the term.
Agreement effective April 28, 2026, running five years from FDA approval of SAB-142
Minimum aggregate spend of $36 million following any FDA approval
Emergent has sole and exclusive right to manufacture the product; batch pricing to be set in a later amendment
Early termination by Emergent for insolvency, non-payment or material breach triggers payment of minimum annual spend for remaining years, less saved costs
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SAB Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →